title: Letter by Imprialos et al Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
authors.affiliation: From Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Imprialos
authors.affiliation: From Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Greece.
authors.forename: Chrysoula
authors.initials: C
authors.lastname: Boutari
authors.affiliation: From Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Greece.
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Stavropoulos
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000188:drug therapy*; D065427:Factor Xa Inhibitors / Q000627:therapeutic use; D006470:Hemorrhage / Q000188:drug therapy; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use; D019338:Polypharmacy; D000069552:Rivaroxaban; D020521:Stroke / Q000188:drug therapy; D014859:Warfarin / Q000627:therapeutic use*
chemical_list: D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009025:Morpholines; D014859:Warfarin; D000069552:Rivaroxaban